Lexaria Bioscience Corp
LEXX
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.35M
Close$
$-1.66
151.4% downside
Current Fair Value
151.4% downsideOvervalued by 151.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.35 Million |
|---|---|
| Enterprise Value | $1.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.9 |
| Beta | 0.34 |
| Outstanding Shares | 1,653,728 |
Return
| Return on Equity | -163.18% |
|---|---|
| Return on Assets | -161.71% |
| Return on Invested Capital | -175.94% |
Valuation & Multiples
| P/E Ratio | -0.61 |
|---|---|
| PEG | 1.28 |
| Price to Sales | - |
| Price to Book Ratio | 1.62 |
| Enterprise Value to Revenue | 10.13 |
| Enterprise Value to EBIT | -0.25 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 13, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.61%▲ 0.52% |
|---|---|
| Total Invested | $920,028▼ 21.15% |
| Investors Holding | 31▲ 3.00% |
ESG Score
No data
About Lexaria Bioscience Corp
3 employeesLexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness...